Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Oxford Nanopore"


4 mentions found


LONDON, Oct 19 (Reuters) - British technology company Oxford Nanopore (ONT.L) said it hoped to reach break-even by the end of 2026, as it outlined plans to drive further growth in the life science research tools market and expand into new areas of healthcare. Oxford Nanopore, a spinout from the University of Oxford which floated two years ago, wants to further commercialise its sensing technology which is able to produce immediate analysis of DNA and RNA for use across scientific research, healthcare and other industries. "Today also marks an important transition for Oxford Nanopore as we introduce our medium-to-long term strategy to meet unmet needs in the clinical and applied markets," Chief Executive Gordon Sanghera said in a statement. For the first half-year of the year, Oxford Nanopore posted a 46% rise in revenues from its Life Science Research Tools unit. Shares in Oxford Nanopore, which has a market capitalisation of 1.6 billion pounds, have fallen 15% in the last six months, prior to Thursday's announcement.
Persons: Oxford Nanopore, Gordon Sanghera, Sarah Young, Kate Holton Organizations: Oxford, University of Oxford, Mayo Clinic, Thomson Locations: British, Oxford
Lab crunch: British science has nowhere to go
  + stars: | 2023-06-20 | by ( Kate Holton | ) www.reuters.com   time to read: +9 min
Property consultants Bidwells put demand for lab space in Cambridge at 1.19 million square feet (110,000 square metres) - but only 7,000 sq ft are available. That has led to an explosion in venture capital, with much of it coming from the United States. Michael Chen moved to Cambridge from the United States in 2012 to do a doctorate in chemistry. She leads a joint venture between Oxford University and Legal & General (LGEN.L) to build lab space and homes. Pioneer Group, which provides funding and lab space in Britain, said action was needed now to address the "crazy" demand.
Persons: Zoe, Toby Melville OXFORD, Ros Deegan, Catherine Elton, Bidwells, Elton, Deegan, Diarmuid O'Brien, Rishi Sunak's, Gordon Sanghera, Michael Chen, Artem Korolev, Anna Strongman, Strongman, Glenn Crocker, Alistair Cory, Qkine's Elton, Kate Holton, Toby Melville, David Clarke Organizations: University of Oxford, Science, REUTERS, European Union, Therapeutics, McKinsey, Oxford, Cambridge Enterprise, U.S, Oxford Nanopore Technologies, Reuters, Company, Cambridge, PACE, Laboratory, Oxford University, Legal, Thomson Locations: Kidlington, Oxford, Britain, England, Cambridge, United States, London, U.S, France, Boston, North America, Europe, Asia, China
According to the Global Innovation Index 2022, global government R&D investment is growing and the UK is ranked fourth for global innovation (and third most innovative economy in Europe). "Space observation is vital for our planet — the UK invests in the European Space Agency and at the Space Cluster at Harwell, a significant science and innovation park." Jo Hawley, deputy director for aerospace, space and automotive at DBT, reported that the UK space sector spent £836 million on R&D in 2021. The company has reported strong growth of its life science research tools business, reflected in the international footprint of its commercial and distribution operations. The Department for Business and Trade can connect you with dedicated, professional assistance to locate R&D investment opportunities and support.
Wall Street is bullish on the California-headquartered company, which makes the enzymes for Pfizer's Covid-19 oral antiviral treatment ; all eight equity analysts covering the stock give it a buy rating. Their median price target points to a 118% potential upside over the 12 months, according to FactSet. "We believe that PRGN's R & D event will validate the key value propositions that underscore PRGN-2012," said Cantor Fitzgerald's analysts in a note to clients on Jan. 12. Other companies on the list include the London-listed stock of Oxford Nanopore Technologies and Genus , which analysts expect to rise by more than 40% over the next 12 months. Clinical diagnostics company Bio-Rad Lab and Sweden-headquartered IVF specialist Vitrolife are the other stocks expected to go up by analysts.
Total: 4